Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib Plus Immunochemoradiotherapy vs Immunochemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma
NCT07385079Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Mar 2026
- Primary completion
- Jan 2028
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of anlotinib in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07385079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07385079.